Priya Bhatt

Priya Bhatt conducts head-to-head translational studies comparing mRNA and peptide-based cancer vaccine platforms for neoantigen immunogenicity and clinical efficacy. Her research has demonstrated that mRNA vaccines can induce more potent and broader CD8+ and CD4+ T cell responses compared to synthetic long peptide vaccines due to efficient antigen presentation. She has characterized how LNP-mRNA vaccines engage dendritic cell cross-presentation pathways critical for CD8+ CTL induction. Her comparative studies inform platform selection for next-generation personalized cancer vaccines.